相关实验视频

Updated: Jun 1, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

病理阶段I肺腺癌的预后分析携带主要EGFR突变的肺腺癌

Shinkichi Takamori¹, Makoto Endo², Akira Hamada³

¹Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan.

Clinical lung cancer

|January 17, 2025

概括

对于具有EGFR突变的早期肺腺癌,缺乏非侵入性区域,更高的病理阶段和淋巴侵入,预测无病生存时间较短. 先进的病理阶段也预测了中枢神经系统的复发.

科学领域:

在瘤学瘤学.
胸部外科手术胸部外科手术
分子病理学分子病理学

背景情况:

表皮生长因子受体 (EGFR) 突变阳性肺腺癌 (LUAD) 对向治疗反应良好.
早期LUAD的预后受病理特征和中枢神经系统 (CNS) 复发风险的影响.
在病态阶段 (pStage) I EGFR 突变的 LUAD 中确定预后因素对于治疗规划至关重要.

研究的目的:

为了确定无病生存 (DFS) 和中枢神经系统复发的独立预后因素,在pStage I EGFR突变的LUAD中.
分析病理特征对手术治疗LUAD患者的大队伍结果的影响.

主要方法:

从2015年至2018年期间,在多个日本机构对2,191个pStage I LUAD病例进行了回顾性分析.
纳入标准:已知EGFR状态,解剖切除和复发后没有EGFR测试.
进行了单变量和多变量分析,以评估DFS和整体存活率 (OS).

主要成果:

在49.0%的病例中存在EGFR突变 (19.1%的19del,24.1%的L858R).
对于主要的EGFR突变,非侵入性区域 (NIA) 的缺失,先进的pStage (IA2-IB与IA1) 和淋巴侵袭独立预测了更短的DFS.
先进的pStage (IA3或更高) 是中枢神经系统复发的唯一独立预测因素.

结论:

没有NIA,较高的pStage和淋巴侵入是EGFR突变的pStage I LUAD中DFS的显著预测因素.
p阶段IA3或更高是这一患者群中中枢神经系统复发的关键风险因素.
这些发现有助于风险分层和早期EGFR突变LUAD的个性化管理.

关键词:

中枢神经系统中枢神经系统皮肤表皮生长因子受体.肺癌是一种肺癌.预后预后预测预测外科手术手术手术

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...